Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2003

View Archived Issues

New phase IIIb studies evaluate Estorra in various patient populations

Capital raised to fund Tranzyme/Neokimia merger

TGN-167 successfully completes phase I trial

Vicuron seeks European approval for anidulafungin

ViroPharma discovers compounds active against New World arenaviruses

Canadian Tectin trial in severe nonmalignant chronic pain cleared to begin

Highlights from the 2003 AACR-NCI-EORTC International Conference available on the LifeSci Channel

Alexion and XOMA collaborate on c-MPL agonist antibody development

ArQule achieves 2003 Pfizer collaboration goals

Array BioPharma and AstraZeneca to develop MEK program for oncology

Phase II Pentrix trial cleared to commence

Photobarr PDT recommended for approval in E.U.

Chiron grants HCV license to Boehringer Ingelheim

Lp-PLA2 targeted for coronary disease

Pyridine-based thyroid receptor modulators described by BMS

Two new series of piperidine derivatives claimed by Procter & Gamble

ICAgen describes new series of potassium channel modulators

Mitotic kinesin KSP inhibitors reported by Cytokinetics and GlaxoSmithKline

Combination of proton pump inhibitor with airway therapeutic claimed by Altana patent

Remodulin: Swiss approval, Australian approval recommendation

NDA filings cover rapid dissolve formulations of Aricept

Phase I trial of VRX-496 modified T-cells continues with third patient

COX17 as a novel target for NSCLC

Novel calpain inhibitor SNJ-1757 identified as anticataract agent with good corneal permeability

L-756867, the first inverse ghrelin agonist, has possible implications for the treatment of obesity

GlaxoSmithKline, Institut Pasteur team up to develop SARS vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...